Copyright
©The Author(s) 2015.
World J Hepatol. Jul 28, 2015; 7(15): 1921-1935
Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1921
Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1921
Ref. | n | Design | Treatment | Outcomes |
Fried et al[32] | - | Retrospective literature review | PEGIFN-α-2a and 2b with RBV, IFN-α -2b/RBV | Across studies, depression occurred in 22% of those treated with PEGIFN-α-2a/RBV, 31% with PEGIFN-α-2b/RBV and 30%-34% of those treated with standard IFN treatment (PEGIFN-α-2b/RBV) |
Fried et al[33] | 1121 | Randomized clinical trial | PEGIFN-α-2a/RBV, IFN-α-2b/RBV, PEGIFN-α-2a | Patients treated with PEGIFN-α-2a plus RBV or placebo had a lower incidence of depression than those treated with IFN-α-2b plus RBV (22% and 20% vs 30%) |
Loftis et al[16] | - | Retrospective literature review | IFN-α, IFN-β, and IFN-γ | Symptoms of depression induced by IFN therapy is common and can limit the treatment utility, often necessitate discontinuation of IFN treatment or the use of psychopharmacologic agents. Depression is also a suspected side effect of therapy with IFN-β and IFN-γ; however, the association has not been as convincingly confirmed |
Hauser et al[34] | - | Retrospective literature review | IFN-α | Neuropsychiatric side effects such as depression, may develop as a result of IFN therapy and lead to lower HRQOL, dose reductions or discontinuation |
Raison et al[35] | 162 | Longitudinal assessment | PEGIFN-α-2b | Moderate to severe depressive symptoms occurred frequently during PEGIFN/RBV treatment and was predicted by baseline depression scores and higher doses of RBV |
Inder et al[37] | 1 | Retrospective case report | IFN-α-2a/RBV | Suicide attempt occurred during IFN-α treatment, improvements were only seen with drug discontinuation. Following re-challenge with combination therapy, patient again experienced suicidal ideation |
Loftis et al[18] | 32 | Prospective cohort study | PEGIFN-α-2a and 2b/RBV | IFN therapy results in a significant increase in depressive symptoms over time, with neuro-vegetative and somatic symptoms of depression increasing more than other depressive symptoms |
- Citation: Hauser P, Kern S. Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World J Hepatol 2015; 7(15): 1921-1935
- URL: https://www.wjgnet.com/1948-5182/full/v7/i15/1921.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i15.1921